Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000704165 | SCV000833103 | uncertain significance | Neuronal ceroid lipofuscinosis | 2022-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 361 of the CLN5 protein (p.Phe361Ser). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with clinical features of neuronal ceroid lipofuscinosis (PMID: 30264640). ClinVar contains an entry for this variant (Variation ID: 580580). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CLN5 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001585653 | SCV001818130 | uncertain significance | not provided | 2021-02-09 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30264640) |
Genome- |
RCV001275305 | SCV002027077 | uncertain significance | Neuronal ceroid lipofuscinosis 5 | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002424701 | SCV002731262 | uncertain significance | Inborn genetic diseases | 2022-06-01 | criteria provided, single submitter | clinical testing | The c.1082T>C (p.F361S) alteration is located in exon 4 (coding exon 4) of the CLN5 gene. This alteration results from a T to C substitution at nucleotide position 1082, causing the phenylalanine (F) at amino acid position 361 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001275305 | SCV001460325 | benign | Neuronal ceroid lipofuscinosis 5 | 2020-04-16 | no assertion criteria provided | clinical testing |